Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function

INTRODUCTION: Approximately one-third of patients with type 2 diabetes mellitus (T2DM) have concurrent renal impairment. There are limited therapeutic options for these patients. Fasiglifam is a G protein-coupled receptor 40 agonist that was under investigation for the treatment of T2DM. The objecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Michael, Nudurupati, Sai, Peng, Xuejun, Marcinak, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269813/
https://www.ncbi.nlm.nih.gov/pubmed/25374042
http://dx.doi.org/10.1007/s40268-014-0066-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269813/
https://www.ncbi.nlm.nih.gov/pubmed/25374042
http://dx.doi.org/10.1007/s40268-014-0066-4

Ejemplares similares